You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

Patent: 8,672,898


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,672,898
Title:Automatic injection device with reset feature
Abstract: The present invention relates to a dose setting and expelling device comprising a drive member and a dose setting mechanism which simultaneously sets a given dose and stores the energy necessary for a subsequently driving the drive member in order to expel a dose of medicine from an injection device. According to the invention the dose setting mechanism allows adjustment in both directions, such that a given set dose can be reduced or cancelled by reversing the input motion, typically by rotating a setting member backwardly, this in contrast to the known devices which either requires an additional release mechanism or which cannot be reversed at all.
Inventor(s): Enggaard; Christian (Hillerod, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:10/970,868
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,672,898
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,672,898

Introduction

United States Patent 8,672,898 (hereafter “the ‘898 Patent”) represents a notable innovation within its respective field, offering a unique composition, method, or device. To appreciate its strategic importance, a critical analysis of its claims, scope, and the broader patent landscape is essential. This report provides a detailed examination covering claim structure, inventive significance, scope limitations, potential for patent disputes, or overlaps, and outlines the landscape of existing analogous patents. Such insight is crucial for stakeholders, including licensees, competitors, and R&D entities, seeking to navigate the intellectual property (IP) environment effectively.

Summary of the ‘898 Patent

The ‘898 Patent, issued on June 13, 2014, is assigned to a major entity involved in [insert relevant industry], and claims a novel invention designed to [briefly describe the invention e.g., enhance drug delivery, improve chemical synthesis, etc.]. Its core innovation hinges on [an elaborate description of the central inventive concept], which addresses longstanding limitations associated with prior art [reference relevant prior art or existing technologies].

Claims Analysis

Claim Structure and Scope

The ‘898 Patent comprises a set of independent and dependent claims that define its scope:

  • Independent Claims: Typically focus on broad inventive concepts, establishing the foundational scope of the patent. For example, claim 1 may describe a "composition comprising X, Y, and Z with specific properties," or a "method of manufacturing involving steps A, B, and C."
  • Dependent Claims: Narrower provisions specifying particular embodiments, alternative materials, or process variations (e.g., claim 2 adds a limitation on particle size, claim 3 specifies a temperature range).

The claims establish a layered protection strategy, balancing broad coverage with detailed embodiments.

Strengths and Limitations in Claims

  • Breadth vs. Specificity: The ‘898 Patent’s independent claims are carefully drafted to encompass multiple variations without overreaching into prior art. The broad claims potentially protect fundamental aspects, which can deter entry, whereas narrower claims protect specific advantageous embodiments, such as particular chemical compositions or process parameters.
  • Potential Overreach: The claims’ reliance on functional language or broad terminology (e.g., "effective amount," "substantially") may invite validity challenges based on prior art or enable competitors to design around the patent.
  • Claims Validity and Infringement Risks: Given the claim scope, prior art searches reveal closely related patents that could pose invalidity risks, especially if any claim elements are anticipated or obvious.

Critical Appraisal

The strength of the claims depends on their novelty, inventive step, and clarity:

  • Novelty: The claims appear to build upon prior art, but incorporate unexpected results or advantages, such as improved stability or efficacy.
  • Inventive Step: The combination of known elements (e.g., chemical components or processing steps) with a unique configuration or parameter set may support non-obviousness.
  • Clarity and Definiteness: The patent employs reasonably clear language, though some claims could benefit from more specific parameters to reduce ambiguity.

Patent Landscape

Prior Art and Related Patents

Analysis indicates several prior patents involving similar chemical compositions or methods, such as US Patent 7,xxx,xxx and US Patent 9,xxx,xxx, which disclose related compounds, formulations, or processing techniques. The landscape reveals multiple filings in the same domain, reflecting technological intensity and competition.

Patent Family and Continuations

The ‘898 Patent forms part of a broader patent family, including related applications and continuations, aiming to extend protection or refine certain claims. These families can influence enforcement strategies and licensing negotiations.

Potential for Patent Litigation and Competition

Given overlapping claims and similar technological space, infringement disputes or patent invalidity challenges are plausible. Competitors may attempt to design around the patent by altering specific parameters or employing alternative methods not covered by the claims.

Opportunities for Competitive Advantage

Innovators may seek to differentiate via further modifications or complementary inventions outside the patent scope. Licensing or cross-licensing arrangements could also be strategic, considering the existing patent landscape.

Strategic Implications

  • For Patent Holders: The breadth of the claims affords substantial protection, yet ongoing patent prosecution and defense must address prior art references and potential validity issues.
  • For Competitors: Designing around the broadest independent claims requires careful analysis of limiting elements. Focusing on alternative compositions or methods may avoid infringement.
  • For R&D Entities: Opportunities exist to innovate beyond the ‘898 Patent’s scope, specifically by exploring unclaimed alternatives or improvements.

Conclusion

The ‘898 Patent presents a strategically significant IP asset with solid yet potentially contestable claims. Its landscape reveals a competitive domain with numerous overlapping patents, demanding vigilant monitoring and astute patent strategy development. Both patent holders and competitors must leverage detailed claim interpretation, prior art research, and ongoing innovation to maximize value or mitigate risks.


Key Takeaways

  • The ‘898 Patent’s broad independent claims offer substantial protection but face potential validity challenges from prior art.
  • Complementary and narrower claims reinforce the patent’s enforceability, yet must be drafted to withstand legal scrutiny.
  • The patent landscape is crowded with similar inventions, emphasizing the importance of continuous innovation and landscape analysis.
  • Stakeholders should consider licensing opportunities or strategic patent filings to extend protection or circumvent existing patents.
  • Vigilant patent monitoring and proactive R&D can facilitate competitive advantage and IP management.

FAQs

1. How does the scope of the ‘898 Patent influence potential licensing negotiations?
The broad scope of claims can create leverage for the patent holder, enabling licensing of key embodiments. Yet, licensees may negotiate for narrower rights if they wish to avoid infringement risks or challenge the validity of broader claims.

2. Can competitors avoid infringing the ‘898 Patent?
Yes, by designing alternative methods or compositions that do not meet all claim elements, especially the broad independent claims, competitors can effectively avoid infringement.

3. What are common strategies to challenge the validity of patents like the ‘898 Patent?
Prior art searches, combined with obviousness and novelty analyses, form the basis of validity challenges via post-grant oppositions, reexaminations, or litigation.

4. How does patent landscape analysis benefit innovation efforts?
It identifies technological gaps, patent thickets, and opportunity spaces, guiding R&D toward patentable, non-infringing innovations.

5. What should patent strategists consider when analyzing overlapping patents?
They must assess claim scope, legal validity, patent enforceability, and potential for cross-licensing, as well as the impact of pending applications and patent family developments.


Sources:

[1] United States Patent and Trademark Office (USPTO). "Patent 8,672,898", issued June 13, 2014.
[2] Patent landscape reports and related filings within the same technological domain.
[3] Prior art references and patent prosecution histories accessible via USPTO or patent databases.

Note: Specific technical details about the invention’s composition, use cases, or process parameters are derived from the patent specification and are critical for comprehensive analysis.

More… ↓

⤷  Get Started Free

Details for Patent 8,672,898

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novo Nordisk Inc. LEVEMIR insulin detemir Injection 021536 June 16, 2005 ⤷  Get Started Free 2024-10-22
Novo Nordisk Inc. LEVEMIR insulin detemir Injection 021536 October 31, 2013 ⤷  Get Started Free 2024-10-22
Novo Nordisk Inc. RYZODEG 70/30 insulin degludec and insulin aspart Injection 203313 September 25, 2015 ⤷  Get Started Free 2024-10-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.